

Index to Volume Nineteen

Index of Issues: January–February 1–60; March–April 61–122; May–June 123–184; July–August 185–242; September–October 243–302; November–December 303–364.

INDEX OF AUTHORS

A

Albritton WL, 279
Alexander WJ, 14
Alfa MJ, 309
Almaraz A, 39
Anderson J, 326
Anderson JE, 320
Andersson B, 140
Aral S, 331
Athey TW, 230
Austin H, 14

B

Baddour LM, 341
Barrett CL, 14
Beebe JL, 47
Beller M, 41
Bernal M, 291
Bharucha H, 225
Bianchi A, 161
Bobo L, 303
Bolan GA, 7
Bollerup AC, 206
Bratos MA, 39
Busby L, 341

C

Caine VA, 99, 351
Carballo M, 219
Carey RF, 230
Carlson RG, 266
Caro-Patón A, 39
Carter RJ, 272
Celentano DD, 175
Chan C-BB, 284
Chang S-J, 335
Cheng SF, 193
Chernesky MA, 243, 315
Clay JC, 298
Cohen DA, 245
Conidou G, 78
Conlon R, 346
Cox KB, 341
Csángó PA, 133, 149

D

Dahlberg LL, 320
Daling JR, 28
Dallabetta G, 88
Daniel RW, 203

Davies AG, 298

Deboer M, 326
Degagne P, 309
Dent C, 245
Desenclos J-CA, 105
Dillon J-AR, 219
Dinsmore WW, 181, 225
Dunnett DM, 92

E

Egglesstone S, 284
Eiros JM, 39
Embil JA, 115

F

Faden RR, 326
Falck R, 266
Farris KB, 272
Felten A, 161
Flaherty EE, 259
Foreman P, 213
Forney MA, 266
Foxman B, 272
Fullilove M, 7
Fullilove R, 7

G

Garrity D, 105
Gaydos CA, 303
Gellin B, 41
Gielen AC, 326
Glassco S, 341
Gnarpe H, 84
Gonzalez JM, 39
Gorter RG, 111
Greenberg J, 331, 346
Gutierrez P, 39
Guzmán J, 291
Guzmán M, 291

H

Haase DA, 115
Hadler SC, 14
Hagdu A, 185
Hahn G, 245
Haivanis RM, 259
Hallén A, 146
Hamed KA, 339
Handley JM, 181, 225

Hart G, 181

Hellberg D, 170
Heller-Vitouch C, 252
Henneberry JF, 47
Herman BA, 230
Herman WA, 230
Hermonat PL, 203
Hill HE, 288
Hillier SL, 198
Hofmann H, 252
Holmes KK, 54
Hook EW III, 88, 175, 213, 243, 303
Horner T, 225
Humphreys JT, 47

I

Ingle D, 41
Jagars G, 149
Jang D, 315
Jarstrand C, 146
Jensen IP, 165
Jetsawangsri T, 295
Joesoef R, 185
Joffe GP, 272
Johnson JK, 341
Jones RB, 99, 243, 351
Jones WE, 259
Judson FN, 243
Juntunen L, 140

K

Kam K-M, 284
Kass N, 326
Kataja V, 154
Katz BP, 99, 351
Kefflew AS, 111
Kelllogg JA, 243
Kennedy CA, 288
Kiviat NB, 54
Knapp JS, 35
Knud-Hansen CR, 88
Kohn R, 7
Kopp W, 252
Ko Y-C, 335
Kreiss JK, 54
Krohn K, 127
Kubicek M, 121
Kunz C, 252

L

Lai C-F, 284
Lassus J, 127
Lawther H, 225
LeBar B, 243
Lee M-F, 193
Li L, 266
Lind I, 206
Lin J-SL, 259
Lou WC, 14
Lutz B, 94
Luz-Jimenez M, 28

M

MacKinnon D, 245
Magder L, 331
Mahony JB, 315
Malyk B, 25
Manley KM, 115
Mäntyjärvi R, 137, 154
Mårdh P-A, 243
Maw RD, 225
McCann DF, 288
McCormack WM, 243
McCray E, 235
McKnight J, 7
McKnight B, 28
Mentis A, 78
Meouchy R, 161
Middaugh J, 41
Miller H, 121
Miller JN, 355
Mogabgab WJ, 94
Montalvo M, 94
Moore DE, 28
Morel P, 161
Moss AR, 111
Moyer MA, 92
Mueller BA, 28
Mumford DM, 19

N

Namaara W, 309
Neumann S, 272
Neumann T, 213
Nugui E, 54
Niemi K-M, 127
Nilsen A, 149
Nugent RP, 198

O	Ray P, 175 Reichert CA, 88, 175, 213 Reimann K, 206 Retta SM, 230 Reynolds G, 185 Rice PA, 259 Rickard RS, 47 Ridgway GL, 243 Rinaldi JE, 230 Roberts PL, 54 Rodríguez-Torres A, 39 Rolfs RT, 7 Ronald AR, 309, 356	Shapiro E, 341 Siegal HA, 266 Skuland J, 149 Slaney L, 309 Smith PB, 19 Spence MR, 25 Spiliopoulou D, 78 Stamm WE, 243 Stary A, 252 Stellato G, 124 Studemester AE, 339 Syrjänen K, 137, 140, 154 Syrjänen S, 127, 140, 154	von Krogh G, 170 Vranizan KM, 111 Vretou E, 78	
P	Paavonen J, 123 Pabst KM, 88 Pahlson C, 146 Pedersen BS, 149 Pereira LH, 115 Perol Y, 161 Pickard L, 315 Plummer F, 54, 309 Portilla I, 94 Psarrou E, 78	Saarikoski S, 137, 154 Salman J, 1 Sarafian SK, 35 Scaggs M, 105 Schachter J, 123, 243 Schiøtz HA, 133 Schmidt AJ, 272 Schnell D, 346 Schwarz SK, 7 Scieux C, 161 Sellors JW, 315 Sell S, 1 Shah KV, 88, 203	Taylor-Robinson D, 243 Tervahauta A, 137 Thompson SE, 185 Tolo K-A, 272 Tsoumaris L, 78	T Wolfe H, 111 Wroten JE, 105 Wu C-H, 193
Q	Quinn TC, 88, 175, 243, 303	Upchurch DM, 175	U Yang D-M, 193 Yan L, 259 Yin S-C, 193 Yliskoski M, 137, 154	
R	Rahm V-A, 84 Ranki A, 127	Vassias I, 161 Viscidi R, 303	V Zenilman JM, 213 Zwickl BW, 351	
			Y Z	

INDEX OF SUBJECTS

A

Abortion applicants, human papillomavirus infection in, 149
 Acquired immunodeficiency syndrome. *See also* Human immunodeficiency virus infection
 in homosexuals, in Taiwan, 335
 knowledge, beliefs, and risk factors for, in inner city adolescent girls, 19
 Adolescents, inner city
 exchange of sex for crack cocaine by, 7
 knowledge, beliefs, and risk factors for HIV infection in, 19
 Adsorption enzyme immunoassay, for *H. ducreyi*, 309
 Age, at first coitus, as high-risk sexual behavior marker, 331
 Alpha 2B interferon, intraleisional, for human papillomavirus-associated cervical intraepithelial neoplasia, 124
 American Social Health Association (ASHA)
 public affairs activities of, 183
 status report for, 301
 Ampicillin/sulbactam with probenecid, vs. ceftriaxone, for gonorrhea, 341
 Anogenital warts. *See* Condylomata acuminata
 Antibiotic resistance, of *Neisseria gonorrhoeae*, temporal trends in, 213
 Antibiotic susceptibility, of *Neisseria gonorrhoeae*, in Hong Kong (1987-1990), 284
 Antibiotic therapy. *See also* specific drugs
 for chlamydia and gonorrhea, compliance with, 351
 Antigen detection tests, for *C. trachomatis*, 315, 161, 243, 259
 Anti-hepatitis C virus antibodies, in FTA-ABS—positive, non-drug abusing prostitutes, 39

ASHA. *See* American Social Health Association (ASHA)
 Axons, cutaneous nerve, *Treponema pallidum* in, 1

B

Bacterial endocarditis, penicillinase-producing *N. gonorrhoeae* and, 288
 Bacterial vaginosis, lactobacilli for, 146
 Barrier methods. *See also* Condoms
 use of, after STD episode, 326
 Biotinylated human papillomavirus DNA probes, for *in situ* hybridization, polymerase chain reaction for production of, 140

C

Cefixime, for uncomplicated gonorrhea, 92
 vs. intramuscular ceftriaxone, 92
 Ceftriaxone
 intramuscular, vs. oral cefixime, for gonorrhea, 94
 vs. ampicillin/sulbactam with probenecid, for gonorrhea, 341
 Cervical infections, effect of on human papillomavirus-associated cervical lesions, 137
 Cervical intraepithelial neoplasia, human papillomavirus-associated
 HPV DNA detection in, by *in situ* hybridization, 225
 intraleisional alpha 2B interferon for, 124
 in Kenyan prostitutes, 54
 Cervicitis, mucopurulent, in prediction of chlamydial infection and adverse pregnancy outcome, 198
 Cervix, human papillomavirus infection of. *See* Human papillomavirus infection

C

Chancroid
adsorption enzyme immunoassay for, 309
HIV infection and, 61
molecular epidemiology of, 35
single-dose spectinomycin for, 291

Chemiluminometric immunoassay (Magic Lite Chlamydia), for *C. trachomatis* antigen, 315, 161

Chlamydia trachomatis
rare serovar Da of, in Greece, 78
gene typing of, by polymerase chain reaction and restriction endonuclease digestion, 303

Chlamydia trachomatis infection
antibiotic therapy for, compliance with, 351
diagnosis of
by chemiluminometric immunoassay (Magic Lite Chlamydia), 315, 161
by polymerase chain reaction, monoclonal antibody-based enzyme immunoassay, and cell culture, 193
urine sample vs. urethral swab for, 165
field follow-up for, 99
HIV infection and, 61
multiple partners and partner choice as risk factors for, in female college students, 272
nonculture tests for, 243, 259
prevalence of, among women attending STD clinic, 88
screening for
by direct fluorescence assay, 84
in pregnancy, mucopurulent cervicitis and, 198
selective, cost-benefit analysis for, 47
test-of-cure consultation for, cost-benefit analysis for, 133
underdiagnosis of, 259

Clinic service, addition of evening hours to, patient attendance and (letter), 181

Coagglutination assay, for monoclonal antibody typing of *N. gonorrhoeae*, 219

Cocaine. *See* Crack cocaine

Coitus, age at first, as high-risk sexual behavior marker, 331

Condoms
latex, barrier effectiveness of, for HIV-sized virus particles, 230
use of
after STD episode, 326
brief promotion programs for, 245
prevalence and patterns of, among STD clinic patients, 175

Condylomata acuminata
anogenital, topical tretinoin for (letter), 181
human papillomavirus DNA detection in, by *in situ* hybridization, 225
penile, diagnosis of, histopathologic vs. demonstration of HPV-specific DNA and proteins, 127
self-treatment of, with podophyllotoxin cream, 170

Contact tracing, for gonorrhea and *C. trachomatis* infection, 99

Crack cocaine use
exchange of sex for money or drugs with, gonorrhea and, 7
high-risk behavior with
for gonorrhea, 7
for HIV infection, 111, 266
for syphilis, 346, 266
with IV drug use, HIV infection and, 111

Cutaneous nerve axons, *Treponema pallidum* in, 1

D

Da serovar, of *C. trachomatis*, in Greece, 78

Diagnostics. *See also* Screening and specific techniques
population-based, in STD laboratory, 279

Direct fluorescence assay, for *C. trachomatis* screening, 84

Direct immunofluorescence tests, for *C. trachomatis*, 243, 259

DNA, human papillomavirus-specific
detection of, by *in situ* hybridization, 225
in diagnosis of penile warts, 127

DNA probes, biotinylated human papillomavirus, polymerase chain reaction for production of, 140

Drug abuse. *See* Crack cocaine

E

Endocarditis, fulminant, penicillinase-producing *N. gonorrhoeae* and, 288

Enzyme immunoassay
for *H. ducreyi*, IX
for monoclonal antibody typing of *N. gonorrhoeae*, 219
vs. polymerase chain reaction and cell culture, for *C. trachomatis* detection, 193

Enzyme-linked immunosorbent assay, for *C. trachomatis*, 243, 259

F

Fertility, pelvic inflammatory disease and, 28, 185

Field follow-up, for gonorrhea and *C. trachomatis* infection, 99

Fitzgerald, Thomas James (obituary), 355

G

Genital ulcer disease, HIV infection and, 61

Gonococcal infection. *See also* Gonorrhea; *Neisseria gonorrhoeae*
endocardial, 288
neonatal, in Florida, 105

Gonococcal ophthalmia neonatorum, in Florida, 105

Gonococci. *See* *Neisseria gonorrhoeae*

Gonorrhea. *See also* Gonococcal infection; *Neisseria gonorrhoeae*
antibiotic therapy for, compliance with, 351
cefazime for, 92
vs. intramuscular ceftriaxone, 92
and exchange of sex for crack cocaine, 7
field follow-up for, 99
HIV infection and, 61, 115
incidence rates for, reinfection and, 41
prevalence of, among women attending STD clinic, 88
single-dose ampicillin/subbactam with probenecid vs. ceftriaxone for, 341

Greece, rare serovar Da of *C. trachomatis* in, 78

H

Haemophilus ducreyi infection. *See* Chancroid

Hepatitis B virus infection, risk factors for, in women, 14

Hepatitis C virus, antibodies to, in FTA-ABS—positive, non-drug abusing prostitutes, 39

Hepatitis C virus infection, sexual transmission of, seroepidemiologic study of, 252

Herpes simplex virus infection, HIV infection and, 61

Homosexuals, sexual patterns and HIV infection in, in Taiwan, 335

Hong Kong, *Neisseria gonorrhoeae* antibiotic susceptibility in, 284

Human immunodeficiency virus, latex condom barrier effectiveness against, 230

Human immunodeficiency virus infection. *See also* Acquired immune deficiency syndrome
cervical intraepithelial neoplasia and, in Kenyan prostitutes, 54
in crack users
high-risk behavior for, 266
with IV drug abuse, 111

- in homosexuals, in Taiwan, 335
- knowledge, beliefs, and risk factors for, in inner city adolescent girls, 19
- new-onset peripartum seizures and, 25
- sentinel surveillance of, 235
- sexually transmitted diseases and, epidemiologic synergy among, 61, 115
 - in STD clinic patients, 115
- Human papillomavirus, nonoxynol-9 inactivation of, 203
- Human papillomavirus-associated cervical intraepithelial neoplasia
 - HPV DNA detection in, by *in situ* hybridization, 225
 - intralesional alpha 2B interferon for, 124
 - in Kenyan prostitutes, 54
- Human papillomavirus DNA detection, by *in situ* hybridization, in anogenital warts and cervical intraepithelial neoplasia, 225
- Human papillomavirus infection
 - in abortion applicants and STD clinic patients, 149
 - HIV infection and, 61
 - lesions in, effect of coexistent cervical infections on, 137
 - multiple partners and partner choice as risk factors for, in female college students, 272
 - prognostic factors in, 154
- Human papillomavirus-specific DNA and proteins, in diagnosis of penile warts, 127

I

- Infertility, pelvic inflammatory disease and, 28, 185
- In situ* hybridization, for human papillomavirus DNA detection, in anogenital warts and cervical intraepithelial neoplasia, 225
- Intercourse, age at first, as high-risk sexual behavior marker, 331
- Interferon, intralesional, for human papillomavirus-associated cervical intraepithelial neoplasia, 124

K

- Kenyan prostitutes, HIV, human papillomavirus, and cervical intraepithelial neoplasia in, 54

L

- Lactobacilli, for bacterial vaginosis, 146

M

- Magic Lite Chlamydia, for *C. trachomatis* antigen detection, 315, 161
- Metronidazole, split-dose, for vaginal trichomoniasis, vs. single-dose tinidazole, 295
- Modified coagglutination assay, for monoclonal antibody typing of *N. gonorrhoeae*, 219
- Monoclonal antibodies, in typing of *N. gonorrhoeae* isolates, 219
- Monoclonal antibody-based enzyme immunoassay, vs. polymerase chain reaction and cell culture, for *C. trachomatis* detection, 193

N

- National Institutes of Health grants, for STD cooperative research centers, 121
- Neisseria gonorrhoeae*. *See also* Gonorrhea
 - antibiotic resistance of, temporal trends in, 213
 - antibiotic susceptibility of, in Hong Kong (1987-1990), 284
 - monoclonal antibody typing of, by enzyme immunoassay and modified coagglutination assay, 219
 - non-penicillinase-producing, novel large plasmid in, 207

- penicillinase-producing
 - carrying 4.9 kb (Toronto) plasmid, 207
 - fulminant endocarditis and, 288
- Nerves, cutaneous, *Treponema pallidum* in axons of, 1
- Newborns, gonococcal infection in, in Florida, 105
- Nonoxynol-9, human papillomavirus inactivation by, 203

O

- Ophthalmia neonatorum, gonococcal, 015

P

- Papillomavirus infection. *See* Human papillomavirus infection
- Parran Award, remarks upon acceptance of, by Allan R. Ronald, 356
- Pelvic inflammatory disease
 - fertility and, 28, 185
 - HIV infection and, 61
- Penile warts, diagnosis of, histopathologic vs. demonstration of HPV-specific DNA and proteins, 127
- Peripartum seizures, new-onset, HIV infection and, 25
- Podophyllotoxin cream, for self-treatment of condylomata acuminata, 170
- Polymerase chain reaction
 - for producing biotinylated human papillomavirus DNA probes for *in situ* hybridization, 140
 - vs. monoclonal antibody-based enzyme immunoassay and cell culture, for *C. trachomatis* detection, 193
 - for gene typing of *C. trachomatis*, with restriction endonuclease digestion, 303
- Population-based diagnostics, 279
- Pregnancy
 - chlamydial infection in, mucopurulent cervicitis in screening for, 198
 - peripartum seizures in, new-onset, HIV infection and, 25
- Prostitutes
 - cervical intraepithelial neoplasia in, HIV and human papillomavirus and, in Nairobi, Kenya, 54
 - crack cocaine-using, high-risk behavior in
 - for gonorrhea, 7
 - for HIV, 266
 - for syphilis, 346, 266
 - FTA-ABS—positive, non-drug abusing, anti-hepatitis C virus antibodies in, 39

R

- Rape victims, sexually transmitted diseases in, 298
- Restriction endonuclease digestion, for gene typing of *C. trachomatis*, with polymerase chain reaction, 303
- Ronald, Allan R., Parran Award winner, 356

S

- Safe sex practices, in patients with prior STD, 326
- Scandinavian Society for Genitourinary Medicine 1990 meeting, papers from, 123-154
- Screening, for *C. trachomatis* infection
 - cost-benefit analysis for, 47
 - by direct fluorescence assay, 84
 - in pregnancy, mucopurulent cervicitis and, 198
- Seizures, new-onset, in peripartum period, HIV infection and, 25

Sexual behavior, high-risk
and age at first coitus, 331
in crack cocaine users, 7, 111, 266
in female college students, 272
in general population, 320
reduction of, after STD episode, 326
Sexually transmitted disease clinic, patient attendance at, with addition
of evening hours (letter), 181
Sexually transmitted disease cooperative research centers, NIH grants
for, 121
Sexually transmitted disease laboratory, population-based diagnostics
and, 279
Sexually transmitted diseases. *See also* specific diseases
and HIV infection, epidemiologic synergy among, 61
multiple partners and partner choice as risk factors for, in female
college students, 272
prevalence of, among women attending STD clinic, 88
prior episode of, and subsequent sexual risk-reduction practices, 326
in women alleging rape, 298
Spectinomycin, single-dose, for chancroid, 291
Spermicide nonoxynol-9, human papillomavirus inactivation by, 203
Substance abuse. *See* Crack cocaine use
Syphilis
high-risk behavior for, in crack cocaine users, 266
HIV infection and, 61, 115

T

Test-of-cure consultation, for *C. trachomatis* infection, cost-benefit
analysis for, 133
Tinidazole
for metronidazole-resistant trichomoniasis, 339

single-dose, for vaginal trichomoniasis, vs. split-dose metronidazole,
295
Toronto (4.9 kb) plasmid, in penicillinase-producing *N. gonorrhoeae*,
207
Treatment compliance, in gonorrhea, 351
Treponemal antibodies, anti-hepatitis C virus antibodies and, in non-
drug abusing prostitutes, 39
Treponema pallidum, in axons of cutaneous nerves, 1
Tretinoin, topical, for anogenital warts, 181
Trichomoniasis
HIV infection and, 61
metronidazole-resistant, tinidazole for, 339
prevalence of, among women attending STD clinic, 88
split-dose metronidazole vs. single-dose tinidazole for, 295
Tubal infertility, pelvic inflammatory disease and, 28, 185

U

Ulcers, genital, HIV infection and, 61
Urethral swab, vs. urine sample, for *C. trachomatis* detection, 315, 165
Urethritis, gonococcal. *See* Gonorrhea
Urine sample, vs. urethral swab, for *C. trachomatis* detection, 315, 165

V

Vaginitis, trichomonal. *See* Trichomoniasis
Vaginosis, bacterial, lactobacilli for, 146
Viral particles, latex condom barrier effectiveness against, 230

W

Warts. *See* Condylomata acuminata